Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants

[1]  J. Karlawish,et al.  The A4 Study: Stopping AD Before Symptoms Begin? , 2014, Science Translational Medicine.

[2]  D. Salmon,et al.  Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults. , 2014, The American journal of psychiatry.

[3]  W. Klunk,et al.  Disclosure of amyloid imaging results to research participants: Has the time come? , 2013, Alzheimer's & Dementia.

[4]  R. Green,et al.  Using AD biomarker research results for clinical care , 2013, Neurology.

[5]  W. Klunk,et al.  Disclosing amyloid imaging results in MCI: What do patients and families want, and why? , 2013, Alzheimer's & Dementia.

[6]  P. Trzepacz,et al.  Testing the use of standardized scripts for disclosing ‘hypothetical/mock’ amyloid PET scan results to nondemented cognitively impaired patients and their care partners , 2013, Alzheimer's & Dementia.

[7]  R. Green,et al.  The psychological impact of genetic risk information on individuals with mild cognitive impairment at imminent risk for conversion to Alzheimer's disease dementia: Findings from the REVEAL Study , 2013, Alzheimer's & Dementia.

[8]  Patricia Desmond,et al.  Microbleeds and clinical trajectories: Results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging , 2013, Alzheimer's & Dementia.

[9]  P. Visser,et al.  The prevalence of amyloid pathology in healthy individuals and individuals with mild cognitive impairment: A meta-analysis of amyloid-PET studies , 2013, Alzheimer's & Dementia.

[10]  J. Roberts,et al.  Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. , 2013, Neurodegenerative disease management.

[11]  Francis Eustache,et al.  Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease , 2013, NeuroImage: Clinical.

[12]  Keith A. Johnson,et al.  Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association , 2013, The Journal of Nuclear Medicine.

[13]  J. Burns,et al.  Should we disclose amyloid imaging results to cognitively normal individuals? , 2013, Neurodegenerative disease management.

[14]  W. Klunk,et al.  Predicting positivity for a new era of Alzheimer disease prevention trials , 2012, Neurology.

[15]  D. Salmon,et al.  Knowledge of APOE genotype affects subjective and objective memory performance in healthy older adults , 2012, Alzheimer's & Dementia.

[16]  W. Klunk,et al.  Development of a standardized approach to disclosing amyloid imaging results in MCI , 2012, Alzheimer's & Dementia.

[17]  R. Green,et al.  Effectiveness of a condensed protocol for disclosing APOE genotype and providing risk education for Alzheimer disease , 2012, Genetics in Medicine.

[18]  R. Green,et al.  Using Alzheimer's disease as a model for genetic risk disclosure: implications for personal genomics , 2011, Clinical genetics.

[19]  J. Karlawish.  Addressing the ethical, policy, and social challenges of preclinical Alzheimer disease , 2011, Neurology.

[20]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[21]  H. Minas,et al.  Where there is no evidence: use of expert consensus methods to fill the evidence gap in low-income countries and cultural minorities , 2010, International journal of mental health systems.

[22]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[23]  Robert Cook-Deegan,et al.  Disclosure of APOE genotype for risk of Alzheimer's disease. , 2009, The New England journal of medicine.

[24]  Suzanne D. Pawlowski,et al.  The Delphi method as a research tool: an example, design considerations and applications , 2004, Inf. Manag..

[25]  T. Marteau,et al.  The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). , 1992, The British journal of clinical psychology.

[26]  J. Yesavage,et al.  Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version. , 1986 .

[27]  M. Horowitz,et al.  Impact of Event Scale: A Measure of Subjective Stress , 1979, Psychosomatic medicine.

[28]  David H. Gustafson,et al.  Group Techniques for Program Planning: A Guide to Nominal Group and Delphi Processes , 1976 .

[29]  Keith A. Johnson,et al.  Preclinical Alzheimer disease—the challenges ahead , 2013, Nature Reviews Neurology.

[30]  E. Sokol.  National plan to address Alzheimer's disease offers hope for new home care and hospice provisions. , 2013, Caring : National Association for Home Care magazine.